New Antibody Targets Severe Asthma

Trial Objective

New Antibody Targets Severe AsthmaThe purpose of this study is to see if a medication called tezepelumab is effective in treating severe asthma and if it causes side effects.

Tezepelumab is a man-made antibody, a protein produced by specific cells in the immune system that react to a substance that the body sees as foreign, such as bacteria or viruses. Tezapelumab reacts with a substance called thymic stromal lymphopoietin (TSLP), which is known to play a role in causing asthma. The Food and Drug Administration (FDA) has not approved tezepelumab for the treatment of asthma. Its use in this study is considered investigational.

Enrollment

This trial is active and currently recruiting.

Who Can Participate

People who have the following may be eligible to participate: (1) poorly controlled asthma for at least 12 months, (2) a physician-prescribed asthma controller with medium- or high-dose inhaled corticosteroid (ICS) such as Flovent®, (3) an additional controller inhaler, including combination inhalers such as Symbicort® or Advair®.

Age: 18-80    Gender: Any Gender


Estimated Time Commitment

19 visits over 69-71 weeks



Compensation

Provided

Trial Contact

For more information, contact:

Allen Stevens

Allen Stevens
303.398.1443

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

AstraZeneca AB

Principal Investigators


Request More Information

*
*
*
*